Cycloserine Drug Susceptibility Testing (DST) for Mycobacterium Tuberculosis – Quantitative MIC Analysis in UAE | 650 AED

Executive Summary & Core Metrics

Cycloserine Drug Susceptibility Testing (DST) precisely measures the minimum inhibitory concentration (MIC) of cycloserine against cultured Mycobacterium tuberculosis isolates, enabling clinicians to construct individualized second-line treatment regimens for multidrug-resistant tuberculosis (MDR-TB).

Accuracy: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited automated fluorescent MIC methodology with quantitative mg/L readouts.
Turnaround Time: Results reported within 21 calendar days from culture receipt – significantly faster than conventional agar proportion methods (28–42 days).
Clinical Support: Complimentary telephonic post-test interpretation session with a DHA-licensed clinician to correlate MIC values with treatment planning.
Insurance & Billing: Direct billing verification available via WhatsApp at +971 54 548 8731.

Test Overview & Methodology

This assay determines the quantitative MIC of cycloserine against cultured Mycobacterium tuberculosis complex using an automated fluorescent microtiter plate system (Sensititre™). The test is indicated for patients with culture-confirmed pulmonary or extrapulmonary tuberculosis who require second-line susceptibility profiling due to confirmed or suspected MDR-TB. Results are interpreted using CLSI M24-A3 and WHO-recommended breakpoints, providing actionable data for personalized therapy.

Parameter	DNA Labs UAE Cycloserine DST	Conventional DST (Alternative Laboratory)
Methodology	Automated Fluorescent Microtiter Plate (Sensititre™) – Quantitative MIC	Agar Proportion Method / MGIT 960 Manual – Qualitative (S/I/R) only
Turnaround Time	21 calendar days	28–42 calendar days
Precision & Output	Quantitative MIC (mg/L) with 99.9% sensitivity; full concentration range reported	Qualitative classification (Susceptible/Intermediate/Resistant) without precise MIC
Standardization	ISO 9001:2015 certified; WHO-endorsed and CLSI M24-A3 compliant	Variable lab-specific protocols; limited inter-laboratory comparability

Physician Insight & Safety Protocols

Dr. Ajay Singh — General Practitioner | DHA Registration ID: 36234132

Cycloserine DST results must always be interpreted within the full clinical context, including prior treatment history, radiological findings, and concurrent susceptibility profiles to other first- and second-line anti-TB drugs. A susceptible MIC result does not guarantee clinical efficacy if the patient has previously failed cycloserine-containing therapy. I strongly advise against any modification of prescribed anti-TB medication without direct oversight from the managing infectious disease physician. Self-adjustment of therapy risks regimen failure, amplification of resistance, and disease progression.

Critical Safety Exclusion & Emergency Flags

Exclusion Criteria: Non-viable or contaminated bacterial culture; insufficient pure growth of Mycobacterium tuberculosis complex; specimen received without maintaining cold-chain integrity (2–8°C). The test cannot be performed on direct patient specimens – a confirmed culture isolate is mandatory.
Requires Immediate Emergency Attention: If you experience sudden high fever exceeding 39°C, hemoptysis (coughing blood), sharp chest pain, or acute respiratory distress, proceed to the nearest emergency department immediately regardless of test results or treatment status.

Medication Advisory

Do not alter, pause, or discontinue any prescribed anti-tuberculosis medication without explicit guidance from your treating physician. Premature discontinuation of therapy can lead to treatment failure, relapse, and acquisition of additional drug resistance, compromising both individual and public health outcomes.

Patient FAQ & Clinical Guidance

1. What is cycloserine drug susceptibility testing, and why might my doctor recommend it?

Cycloserine DST measures the minimum inhibitory concentration (MIC) – the lowest concentration of cycloserine that stops the growth of your cultured Mycobacterium tuberculosis isolate. This quantitative result tells your doctor whether the strain is susceptible or resistant to cycloserine, which is a second-line antibiotic used specifically for multidrug-resistant TB (MDR-TB). The test is recommended when you have culture-confirmed TB and either confirmed resistance to first-line drugs (rifampin/isoniazid) or clinical suspicion of MDR-TB based on prior treatment history or exposure to known drug-resistant cases.

2. How is this test performed, and what is the expected turnaround time for results?

A pure culture of Mycobacterium tuberculosis complex grown from your clinical specimen (e.g., sputum, bronchoalveolar lavage, or biopsy tissue) is exposed to a calibrated concentration range of cycloserine in an automated fluorescent microtiter plate system. Bacterial growth is measured fluorometrically to determine the precise MIC value. Results are reported within 21 calendar days from the date a viable, uncontaminated culture is received in the laboratory. This is significantly faster than conventional agar proportion methods that require 28–42 days.

3. What do I need to do to prepare for this test?

No special patient preparation is required because the test is performed on a bacterial culture, not directly on you. However, you must have a confirmed positive culture of Mycobacterium tuberculosis complex before this susceptibility test can be ordered. If you are currently receiving anti-TB treatment, continue taking all medications exactly as prescribed. Your doctor will coordinate the collection of the appropriate specimen for culture, which is a hospital-based procedure requiring sterile collection techniques.

4. How are the MIC results used in my treatment plan?

The quantitative MIC value (reported in mg/L) is compared against established CLSI and WHO clinical breakpoints to classify your isolate as susceptible, intermediate, or resistant to cycloserine. Your infectious disease physician will incorporate this result alongside other DST results (for fluoroquinolones, aminoglycosides, bedaquiline, linezolid, etc.) and your clinical history to construct a fully individualized MDR-TB regimen. A susceptible result supports the inclusion of cycloserine in your regimen at an appropriate dose, while a resistant result prompts selection of an alternative second-line agent.

5. Are there any risks or limitations associated with the test?

The test itself poses no direct risk to you because it is performed on an already-cultured bacterial isolate. The primary limitation is that a viable, uncontaminated pure culture is required – contaminated cultures or those with insufficient growth cannot be tested and will require recollection. Additionally, cycloserine DST may not detect heteroresistance (mixed susceptible and resistant bacterial populations) that can emerge during therapy. Serial susceptibility testing may be recommended if you show a delayed clinical or microbiological response to treatment.

UAE Regulatory & Data Privacy Adherence

Data Protection & Clinical Compliance Framework

All clinical data, test results, and patient identifiable information associated with Cycloserine DST are processed, stored, and transmitted in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent for diagnostic testing and data handling is obtained and documented in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE operates under ISO 9001:2015 quality management certification (Cert. No. INT/EGQ/2509DA/3139) ensuring end-to-end data integrity, access control, and confidential result delivery. No patient data is shared with third parties without explicit written consent except where required by applicable UAE law.

Clinical & Logistical Metadata

Test Name	Cycloserine Drug Susceptibility Testing (DST) – Quantitative MIC – Mycobacterium tuberculosis Complex
Price (AED)	650 AED
Turnaround Time	21 calendar days from receipt of viable pure culture isolate
Sample Type / Matrix	Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. Specimen required: Pure culture isolate of Mycobacterium tuberculosis complex grown on solid (Lowenstein-Jensen) or liquid (MGIT) media. Initial clinical specimen (sputum, BAL, tissue biopsy) must be collected under sterile conditions in a hospital setting.
Methodology Used	Automated Fluorescent Microtiter Plate (Sensititre™) – Quantitative MIC Determination – CLSI M24-A3 compliant
ICD-10-CM Code	Z01.84, U84.3
LOINC Code	52039-2
DHA Facility License & Laboratory Address	DHA Facility License Number: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE